{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:08Z","timestamp":1761871448276,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clml.2020.01.013","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T19:20:12Z","timestamp":1584127212000},"page":"e316-e319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Paraneoplastic Cholestasis in Relapsed\/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade"],"prefix":"10.1016","volume":"20","author":[{"given":"Gopisree","family":"Peringeth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.01.013_bib1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1080\/02841860701644078","article-title":"Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review","volume":"47","author":"Ballonoff","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clml.2020.01.013_bib2","series-title":"Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases","first-page":"921","article-title":"Biliary ductopenia (vanishing bile duct syndrome)","author":"Dancygier","year":"2010"},{"key":"10.1016\/j.clml.2020.01.013_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CLM.2006.n.044","article-title":"Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin\u2019s lymphoma","volume":"7","author":"Barta","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2020.01.013_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042737-200203000-00019","article-title":"Hodgkin\u2019s disease presenting as cholestatic hepatitis with prominent ductal injury","volume":"14","author":"Liangpunsakul","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2020.01.013_bib5","first-page":"987860","article-title":"Idiopathic intrahepatic cholestasis as an unusual presentation of Hodgkin\u2019s disease","volume":"2015","author":"Atalay","year":"2015","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2020.01.013_bib6","first-page":"430","article-title":"Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin\u2019s disease","volume":"24","author":"Gottrand","year":"1997","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clml.2020.01.013_bib7","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1097\/01.mcg.0000155549.29643.ad","article-title":"Pathophysiology of cholangiopathies","volume":"39","author":"Strazzabosco","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.clml.2020.01.013_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hep.1840170114","article-title":"Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin\u2019s lymphoma","volume":"17","author":"Hubscher","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2020.01.013_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3748\/wjg.v23.i2.366","article-title":"Vanishing bile duct syndrome in Hodgkin\u2019s lymphoma: a case report and literature review","volume":"23","author":"Bakhit","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2020.01.013_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000012005","article-title":"Extrahepatic Hodgkin\u2019s disease with intrahepatic cholestasis: report of two cases","volume":"57","author":"Yal\u00e7in","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2020.01.013_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MEG.0b013e3282b9e6c2","article-title":"Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin\u2019s lymphoma, fully reversible after chemotherapy","volume":"20","author":"Leeuwenburgh","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2020.01.013_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.kjms.2013.05.002","article-title":"Hodgkin\u2019s lymphoma-related vanishing bile duct syndrome: a case report and literature review","volume":"29","author":"Wong","year":"2013","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.clml.2020.01.013_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1756-0500-7-529","article-title":"Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin\u2019s lymphoma: a case report and review of the literature","volume":"7","author":"Rota Scalabrini","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clml.2020.01.013_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227676","article-title":"Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin\u2019s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure","volume":"12","author":"Fong","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clml.2020.01.013_bib15","first-page":"1038","article-title":"Cholestasis secondary to Hodgkin\u2019s disease: report of 2 cases of vanishing bile duct syndrome","volume":"83","author":"de Medeiros","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.013_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/030089160409000516","article-title":"Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) in Hodgkin\u2019s disease: report of a case","volume":"90","author":"Guliter","year":"2004","journal-title":"Tumori"},{"key":"10.1016\/j.clml.2020.01.013_bib17","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/MPH.0b013e31818b37c4","article-title":"Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature","volume":"30","author":"Pass","year":"2008","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2020.01.013_bib18","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1177\/030089161309900426","article-title":"Vanishing bile duct syndrome as a manifestation of Hodgkin\u2019s lymphoma: a case report and review of the literature","volume":"99","author":"Nader","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.clml.2020.01.013_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/1319-3767.121037","article-title":"Vanishing bile duct syndrome in a Hodgkin\u2019s lymphoma patient with fatal outcome despite lymphoma remission","volume":"19","author":"Aleem","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.clml.2020.01.013_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2020.01.013_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2015-10-671826","article-title":"How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant","volume":"127","author":"Alinari","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.013_bib22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.013_bib23","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.013_bib24","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.013_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00277-001-0406-7","article-title":"Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin\u2019s disease","volume":"81","author":"K\u00f6m\u00fcrc\u00fc","year":"2002","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:30Z","timestamp":1761870870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2152265020300501"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Treatment of Paraneoplastic Cholestasis in Relapsed\/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}